Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2016-12-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
关于收购盛世君晖生化全线产品业务的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of a biochemical product business line by Zhengzhou Antu Biological Engineering Co., Ltd. It includes extensive financial evaluation, valuation methods (discounted cash flow, CAPM), comparison with industry peers, and strategic rationale for the acquisition. The content focuses on the acquisition transaction, valuation, and business integration rather than financial results or earnings. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a simple announcement of a report publication but a substantive disclosure about a capital transaction. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions.
2016-12-29 Chinese
拟收购香港盛世君晖科技发展有限公司东芝医疗生化全线产品中国区销售业务评估项目资产评估报告书
Regulatory Filings
2016-12-26 Chinese
独立董事关于公司第二届董事会第九次会议相关事项的独立意见
Regulatory Filings
2016-12-23 Chinese
董事、监事和高级管理人员持有本公司股份及其变动管理制度
Governance Information Classification · 95% confidence The document is a detailed internal management system outlining the rules and procedures for the holding and trading of company shares by directors, supervisors, and senior management personnel. It includes regulatory references, restrictions on trading periods, reporting and disclosure obligations, and penalties for violations. The content focuses on governance and compliance related to insider share dealings rather than financial results, audit opinions, or shareholder meeting materials. It does not contain financial statements, earnings data, or voting results. The document is a governance-related policy document concerning insider shareholding and trading management, fitting the category of Governance Information (CGR).
2016-12-23 Chinese
第二届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's board of directors meeting, including decisions on acquisitions, management shareholding policies, amendments to the company's articles, and scheduling of a shareholders meeting. It includes voting results and references to related announcements published elsewhere. The content focuses on board meeting decisions and governance matters rather than financial results or reports. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report itself but a meeting resolution announcement, confirming the classification.
2016-12-23 Chinese
关于变更经营范围及修订公司章程的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding changes to the company's business scope and amendments to the company charter. It details the specific changes in business activities and the corresponding revisions to the articles of association. The announcement states that these changes were approved by the board and supervisory committee and will be submitted to the shareholders' meeting for approval. There is no financial data, audit information, or report attached. The document is a formal corporate announcement about management decisions and governance changes, specifically about the company's operational scope and charter amendments. This fits best under Board/Management Information (MANG) as it relates to corporate governance and management decisions rather than a full report or regulatory filing.
2016-12-23 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.